Bio Tech General Isn't Stunted Yet

Bio-Technology General (BTGC) is still recovering from the one-two punch the Food & Drug Administration delivered early this year, knocking it from its 1998 high of 10 to 6 5/8. But not everyone is scared. Michael Petusky of Branch Cabell, a Richmond (Va.) investment firm, calls the stock "significantly undervalued given its growth potential." It trades at 9 times his 1999 profit estimate of 46 cents a share. His target: 11 1/2. Bio-Technology, among the few profitable biotechs, is expected to have revenues of $80 million this year, up from 1997's $65.3 million.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.